Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvele Tablets, 800 mg, of Genzyme Corporation.
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Sevelamer Carbonate Tablets (RLD: Renvele) had estimated annual sales of USD 348 million in the U.S. (IQVIA MAT September 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.1079.55 as compared to the previous close of Rs. 1068.35. The total number of shares traded during the day was 138073 in over 6258 trades.
The stock hit an intraday high of Rs. 1088.7 and intraday low of 1056.75. The net turnover during the day was Rs. 148229951.